Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (NASDAQ:BBNX), filed a Form 4 on November 9, 2026, disclosing a same-day option exercise and sale of 382 shares of common stock on November 5, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Option exercised: Feider exercised an employee stock option covering 382 shares of common stock at an exercise price of $5.10 per share on November 5, 2026.
  • Shares sold: 382 shares of common stock were disposed of on November 5, 2026, at a weighted average sale price of $17.036649, with individual prices ranging between $17.00 and $17.07.
  • 10b5-1 plan: According to the filing, the sale was made pursuant to a Rule 10b5-1 plan adopted on July 31, 2026.
  • Remaining direct holdings: Following the transactions, Feider directly beneficially owned 159,378 shares of common stock.
  • Remaining options: Feider directly held 39,313 employee stock options with an exercise price of $5.10, expiring September 13, 2033, following the reported transactions.
  • Option vesting: The filing states the option shares vest in 48 equal monthly installments measured from September 14, 2023.

Feider's November 5 Option Exercise and Sale at Beta Bionics

According to the Form 4 filed with the SEC on November 9, 2026, Beta Bionics CFO Stephen Feider reported two transactions in the company's common stock on November 5, 2026. First, Feider exercised an employee stock option (transaction code M) for 382 shares at an exercise price of $5.10 per share, increasing his direct beneficial ownership to 159,760 shares following that acquisition.

Immediately following the exercise, the filing reports that Feider disposed of 382 shares (transaction code S) at a weighted average sale price of $17.036649, with the range of individual sale prices falling between $17.00 and $17.07. The filing notes that full information on the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or any security holder. After the sale, Feider's direct beneficial ownership in Beta Bionics common stock stood at 159,378 shares, according to the filing.

The filing discloses that the sale was executed pursuant to a Rule 10b5-1 trading plan that Feider adopted on July 31, 2026. With respect to the underlying option, the filing states that the shares subject to the option vest in 48 equal monthly installments measured from September 14, 2023, and that the option carries an expiration date of September 13, 2033. Following the reported exercise, Feider directly held 39,313 employee stock options at an exercise price of $5.10. The Form 4 was signed by Thomas Sohn as Attorney-in-Fact on November 9, 2026.

What Was Disclosed

The filing reports a November 5, 2026, option exercise and same-day sale of 382 Beta Bionics common shares by CFO Stephen Feider under a pre-established Rule 10b5-1 plan, leaving him with direct beneficial ownership of 159,378 shares and 39,313 remaining options.